Centocor
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Centocor sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
Centocor: 33 sponsored US clinical trials, none currently recruiting.
Centocor sponsors 33 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 31 completed. 9 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 1 trials.
Top-decile sponsor footprint
Centocor ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
31 of 33 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
33 total, page 1 of 1
A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects
NCT01258777
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
NCT01204996
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
NCT00955279
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
NCT00973479
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis
NCT00925574
A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors
NCT00841191
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
NCT00882726
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT00786201
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
NCT00771667
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT00718718
A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
NCT02074800
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)
NCT01362153
A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector
NCT00643526
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
NCT00537381
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
NCT00458575
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
NCT00385827
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
NCT00402181
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT00361335
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
NCT00336492
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
NCT00380796
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
NCT00299546
A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive
NCT00264537
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
NCT00265096
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
NCT00267956
An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT00264550
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis
NCT00265083
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
NCT00401765
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
NCT00246012
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
NCT00412321
A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma
NCT00207740
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
NCT00265122
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
NCT00046228
A Long-term Safety Study of Infliximab (Remicade)
NCT00261976
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 10 |
| Phase 3 | 9 |
Therapeutic Areas
How the Centocor early-phase archive is shaped
33 indexed studies, none listed as recruiting (0% open); 31 completed (94%).
Phase mix: 9 late (III/IV) vs 22 early (I/II) (early-phase heavy).
Top condition: Pulmonary Disease, Chronic Obstructive (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Centocor: archived-pipeline peers nationwide
Peers matched on 33 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Centocor sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 archived trials
- Aclaris Therapeutics · 33 trials · 3% recruiting
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Centocor page
33 registered trials is a research-attention snapshot, not an endorsement of Centocor or any single study.
- None of Centocor's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Pulmonary Disease, Chronic Obstructive is the condition Centocor studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Centocor pipeline card: 33 registered trials from official public datasets.Report a data error.